MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
-11.01%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$645M
AUM Growth
+$645M
(+5.9%)
Cap. Flow
+$142M
Cap. Flow
% of AUM
22.05%
Top 10 Holdings %
Top 10 Hldgs %
72.39%
Holding
33
New
19
Increased
7
Reduced
3
Closed
–
Top Buys
| 1 |
Intellia Therapeutics
NTLA
|
$21.8M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
$10.1M |
| 3 |
Cytokinetics
CYTK
|
$8.84M |
| 4 |
Verastem
VSTM
|
$8.7M |
| 5 |
EPZM
Epizyme, Inc
EPZM
|
$8.4M |
Top Sells
| 1 |
iTeos Therapeutics
ITOS
|
$6.25M |
| 2 |
Cullinan Oncology
CGEM
|
$6M |
| 3 |
Repare Therapeutics
RPTX
|
$951K |
Sector Composition
| 1 | Healthcare | 94.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cullinan Oncology
CGEM
$445M
| $173M | 26.78% | 7,648,268 -265,619 | -3% | -$6M |
|
|
2
iTeos Therapeutics
ITOS
| $56.9M | 8.82% | 2,107,092 -231,489 | -10% | -$6.25M |
|
|
3
Repare Therapeutics
RPTX
$71.7M
| $43M | 6.67% | 1,639,849 -36,238 | -2% | -$951K |
|
4
Werewolf Therapeutics
HOWL
$59.9M
| $41M | 6.36% | 2,388,011 | – | – |
|
|
TCRR
5
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $28.7M | 4.45% | 3,370,982 | – | – |
|
|
HARP
6
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $25.3M | 3.92% | 3,196,707 | – | – |
|
|
ONCR
7
DELISTED
Oncorus, Inc.
ONCR
| $22.2M | 3.44% | 2,377,031 | – | – |
|
|
8
Intellia Therapeutics
NTLA
$1.22B
| $21.8M | 3.38% | +162,620 | New | +$21.8M |
|
9
Merus
MRUS
$4.98B
| $20.7M | 3.21% | 941,948 +241,069 | +34% | +$5.3M |
|
|
EPZM
10
DELISTED
Epizyme, Inc
EPZM
| $20.3M | 3.16% | 3,972,830 +1,641,296 | +70% | +$8.4M |
|
|
TPTX
11
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $18M | 2.8% | 271,350 +2,164 | +0.8% | +$144K |
|
12
Y-mAbs Therapeutics
YMAB
$388M
| $12.9M | 2.01% | 452,970 +115,679 | +34% | +$3.3M |
|
|
GTHX
13
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $11.5M | 1.79% | 860,502 +47,708 | +6% | +$640K |
|
|
14
BioCryst Pharmaceuticals
BCRX
$1.74B
| $10.1M | 1.57% | +704,767 | New | +$10.1M |
|
15
ADC Therapeutics
ADCT
$345M
| $9.36M | 1.45% | 344,519 +126,492 | +58% | +$3.44M |
|
|
16
Cytokinetics
CYTK
$4.23B
| $8.84M | 1.37% | +247,291 | New | +$8.84M |
|
|
17
Verastem
VSTM
$569M
| $8.7M | 1.35% | +2,824,857 | New | +$8.7M |
|
18
Geron
GERN
$893M
| $7.85M | 1.22% | +5,732,770 | New | +$7.85M |
|
19
Travere Therapeutics
TVTX
$1.56B
| $7.43M | 1.15% | +306,515 | New | +$7.43M |
|
20
NeoGenomics
NEO
$1.13B
| $7.21M | 1.12% | +149,504 | New | +$7.21M |
|
21
Crinetics Pharmaceuticals
CRNX
$2.92B
| $6.28M | 0.97% | +298,392 | New | +$6.28M |
|
22
Mirum Pharmaceuticals
MIRM
$3.71B
| $6.15M | 0.95% | +308,532 | New | +$6.15M |
|
23
Harmony Biosciences
HRMY
$2.12B
| $5.81M | 0.9% | +151,650 | New | +$5.81M |
|
24
ESSA Pharma
EPIX
$11.4M
| $5.47M | 0.85% | +683,287 | New | +$5.47M |
|
25
Amicus Therapeutics
FOLD
$2.34B
| $5.22M | 0.81% | +546,558 | New | +$5.22M |
|